JFL Life

Which are the latest news on JFL Life?

Why is JFL Life Sciences Ltd falling/rising?

As of 05-Sep, JFL Life Sciences Ltd's stock price is slightly rising at 9.85, influenced by positive short-term factors like increased investor participation and strong quarterly results, despite a long-term decline of 32.53% over the past year. The stock remains below all moving averages, indicating ongoing challenges.

As of 05-Sep, JFL Life Sciences Ltd's stock price is rising slightly, currently at 9.85, reflecting a change of 0.05 (0.51%) upward. This increase can be attributed to a few positive factors despite the overall negative performance of the stock in the longer term. Notably, the company has shown healthy long-term growth, with net sales increasing at an annual rate of 32.00% and operating profit growing at 41.41%. Furthermore, the company has declared positive results for the last three consecutive quarters, with net sales for the first nine months growing by 126.59% and profit after tax increasing by 205.10%.<BR><BR>Additionally, there has been a notable rise in investor participation, with delivery volume on September 3 increasing by 194.12% compared to the five-day average. This suggests a growing interest in the stock, which may contribute to the recent uptick in price. However, it is important to note that despite this short-term rise, the stock has significantly underperformed in the long term, with a decline of 32.53% over the past year and a negative return of 43.39% over the last three years. The stock is also trading below all its moving averages, indicating a bearish trend overall. Thus, while there is a slight rise in price, the broader context shows ongoing challenges for JFL Life Sciences Ltd.

Who are in the management team of JFL Life?

The management team of JFL Life includes Smiral Ashwinkumar Patel (Managing Director), Manishkumar Jasvantlal Patel (Chairman & Non-Executive Director), Tejal Smiral Patel (Whole-time Director), Sonu Lalitkumar Jain (Non-Executive & Independent Director), Bhavna Shah (Non-Executive & Independent Director), and Pratima Singh (Company Secretary).

The management team of JFL Life includes the following individuals:<BR><BR>1. **Smiral Ashwinkumar Patel** - Managing Director<BR>2. **Manishkumar Jasvantlal Patel** - Chairman & Non-Executive Director<BR>3. **Tejal Smiral Patel** - Whole-time Director<BR>4. **Sonu Lalitkumar Jain** - Non-Executive & Independent Director<BR>5. **Bhavna Shah** - Non-Executive & Independent Director<BR>6. **Pratima Singh** - Company Secretary<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

What does JFL Life do?

JFL Life Sciences Ltd is a Micro Cap company that manufactures and markets pharmaceutical products. As of June 2026, it reported net sales of 11 Cr and a net profit of 1 Cr, with a market cap of INR 35 Cr.

Overview: <BR>JFL Life Sciences Ltd manufactures and markets pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>JFL Life Sciences Ltd was incorporated as 'JFL Life Sciences Private Limited' on April 25, 2010. The company transitioned from a Private Limited to a Public Limited Company following a Special Resolution on February 10, 2022, and subsequently changed its name to 'JFL Life Sciences Limited' on March 3, 2022. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 11 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 35 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 5.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.44 <BR>Return on Equity: 14.74% <BR>Price to Book: 0.77 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the JFL Life?

JFL Life's peers include Medicamen Organ., Lasa Supergeneri, Sandu Pharma., Vista Pharma., Chandra Bhagat, Medi Caps, ANG Lifesciences, Guj. Terce Labs., and Cian Healthcare. JFL Life exhibits excellent management and growth, while its peers generally show average to below-average performance in these areas.

Peers: The peers of JFL Life are Medicamen Organ., Lasa Supergeneri, Sandu Pharma., Vista Pharma., Chandra Bhagat, Medi Caps, ANG Lifesciences, Guj. Terce Labs., and Cian Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at JFL Life, while Average management risk is found at Sandu Pharma. and the rest. Below Average management risk is present at Medicamen Organ., Lasa Supergeneri, Vista Pharma., Chandra Bhagat, Medi Caps, ANG Lifesciences, Guj. Terce Labs., and Cian Healthcare. JFL Life shows Excellent growth, while Average growth is noted at Medi Caps and the rest. Below Average growth is seen at Medicamen Organ., Lasa Supergeneri, Sandu Pharma., Vista Pharma., Chandra Bhagat, ANG Lifesciences, Guj. Terce Labs., and Cian Healthcare. JFL Life has a Good capital structure, while Good capital structure is also found at Sandu Pharma. and Medi Caps. Below Average capital structure is observed at Medicamen Organ., Lasa Supergeneri, Vista Pharma., Chandra Bhagat, ANG Lifesciences, Guj. Terce Labs., and Cian Healthcare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Medicamen Organ. at -29.63%, while JFL Life has a 1-year return of -29.00%, which is slightly better. The peer with the lowest 1-year return is also Medicamen Organ. at -29.63%. Additionally, peers such as Lasa Supergeneri, Vista Pharma., Chandra Bhagat, ANG Lifesciences, Guj. Terce Labs., and Cian Healthcare have a six-month return of 0.00%.

How big is JFL Life?

As of 31st August, JFL Life Sciences Ltd has a market capitalization of 35.00 Cr, with recent Net Sales of 130.90 Cr and a Net Profit of 6.76 Cr. Shareholder's Funds are 39.46 Cr and Total Assets amount to 71.91 Cr as of March 2025.

As of 31st August, JFL Life Sciences Ltd has a market capitalization of 35.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, JFL Life reported Net Sales of 130.90 Cr and a Net Profit of 6.76 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 39.46 Cr and Total Assets of 71.91 Cr.

Should I buy, sell or hold JFL Life Sciences Ltd?

Are JFL Life Sciences Ltd latest results good or bad?

JFL Life Sciences Ltd's latest results show strong revenue growth of 437.51% year-on-year, but a 17.82% decline in net profit and reduced operating margins indicate operational challenges. Overall, the results are considered unfavorable, leading to a "SELL" rating.

JFL Life Sciences Ltd's latest results present a mixed picture, leaning towards the negative side. In Q4 FY26, the company reported a significant revenue increase of 437.51% year-on-year, reaching ₹63.05 crores, which is commendable. However, this impressive topline growth came at a cost, as the net profit declined by 17.82% quarter-on-quarter to ₹1.66 crores. <BR><BR>The operating margin also suffered, dropping to 5.57% from 12.48% in the previous quarter, indicating that the revenue growth was not translating into profitability. This margin compression raises concerns about the sustainability of the growth achieved. Additionally, the company has faced severe headwinds over the past year, with its stock price declining by 52.88%, significantly underperforming both the Sensex and its pharmaceutical sector peers.<BR><BR>Overall, while the revenue growth is a positive sign, the decline in profit and margins suggests underlying operational challenges that need to be addressed. The current "SELL" rating and a Mojo score of 37 out of 100 reflect these concerns, indicating that the latest results are not favorable for investors.

How has been the historical performance of JFL Life?

JFL Life has shown significant growth in net sales and profitability, with net sales increasing from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, and profit after tax rising from 0.36 Cr to 4.16 Cr during the same period. However, cash flow from operations has been volatile, turning negative at -3.00 Cr in Mar'25.

Answer:<BR>The historical performance of JFL Life shows a significant growth trend in net sales and profitability over the past few years.<BR><BR>Breakdown:<BR>JFL Life's net sales have increased from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, indicating a robust growth trajectory. Total operating income has followed a similar pattern, rising from 30.17 Cr to 82.04 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, reaching 73.85 Cr in Mar'25 from 28.31 Cr in Mar'20. Operating profit, which reflects the company's operational efficiency, has improved from 1.86 Cr in Mar'20 to 8.20 Cr in Mar'25, while profit before tax has increased from 0.50 Cr to 6.14 Cr in the same timeframe. Profit after tax has also seen a rise from 0.36 Cr in Mar'20 to 4.16 Cr in Mar'25. The company's earnings per share (EPS) have fluctuated, peaking at 10.8 in Mar'21 before settling at 1.26 in Mar'25. On the balance sheet, total assets have grown from 48.26 Cr in Mar'22 to 71.91 Cr in Mar'25, with total liabilities also increasing from 48.26 Cr to 71.91 Cr. The cash flow from operating activities has been negative in Mar'25 at -3.00 Cr, contrasting with a positive cash flow of 8.00 Cr in Mar'24. Overall, JFL Life has demonstrated significant growth in sales and profitability, although cash flow from operations has shown volatility.

How has been the historical performance of JFL Life?

JFL Life has shown significant growth in net sales and profitability, with net sales increasing from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, and profit after tax rising from 0.36 Cr to 4.16 Cr during the same period, despite some cash flow challenges. Total assets and liabilities also grew, reflecting the company's expanding operations.

Answer:<BR>The historical performance of JFL Life shows a significant upward trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>JFL Life's net sales have increased from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, reflecting a strong growth trajectory. Total operating income followed a similar pattern, rising from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25. The raw material costs also rose, from 26.72 Cr in Mar'20 to 66.77 Cr in Mar'25, indicating increased production expenses. Operating profit, excluding other income, improved from 1.86 Cr in Mar'20 to 8.19 Cr in Mar'25, while profit before tax increased from 0.50 Cr to 6.14 Cr in the same period. Profit after tax also saw a rise from 0.36 Cr in Mar'20 to 4.16 Cr in Mar'25. The company's total assets grew from 48.26 Cr in Mar'22 to 71.91 Cr in Mar'25, with total liabilities increasing from 48.26 Cr to 71.91 Cr. Cash flow from operating activities showed fluctuations, with a negative cash flow of -3.00 Cr in Mar'25, contrasting with a positive cash flow of 8.00 Cr in Mar'24. Overall, JFL Life has demonstrated robust growth in sales and profitability, despite some challenges in cash flow management.

Who are the top shareholders of the JFL Life?

The top shareholder of JFL Life is Smiral Ashwinkumar Patel, holding 44.33% of the shares. The highest public shareholder is Pratik Rajendra Gandhi at 1.22%, while individual investors collectively own 28.99%.

The top shareholders of JFL Life primarily include the promoters, with Smiral Ashwinkumar Patel holding the largest share at 44.33%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Pratik Rajendra Gandhi, who owns 1.22%. Additionally, individual investors collectively hold 28.99% of the shares.

Is JFL Life overvalued or undervalued?

As of May 20, 2025, JFL Life is considered undervalued with a PE ratio of 15.59 and an EV to EBITDA of 8.61, showing significant improvement and potential for recovery despite a year-to-date decline of 39.02% compared to the Sensex's 6.24%.

As of 20 May 2025, JFL Life has moved from a grade of does not qualify to very attractive, indicating a significant improvement in its valuation outlook. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 15.59, an EV to EBITDA of 8.61, and a ROCE of 17.46%. <BR><BR>In comparison to its peers, JFL Life stands out with a much lower PE ratio than Sun Pharmaceutical Industries Ltd. at 35.25 and Divi's Laboratories Ltd. at 79.33, both of which are classified as expensive. The valuation metrics suggest that JFL Life is positioned favorably within the pharmaceuticals and biotechnology sector. Despite recent underperformance relative to the Sensex, with a year-to-date decline of 39.02% compared to the Sensex's 6.24%, the current valuation indicates a potential for recovery and growth.

What is the technical trend for JFL Life?

As of May 21, 2025, JFL Life's technical trend is mildly bearish, supported by negative signals from daily moving averages, Bollinger Bands, and KST, despite a mildly bullish weekly MACD.

As of 21 May 2025, the technical trend for JFL Life has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD is mildly bearish, suggesting mixed signals. The moving averages on the daily chart are also mildly bearish, reinforcing the negative outlook. Bollinger Bands and KST on the weekly are both bearish, while the Dow Theory shows a bearish trend on the weekly timeframe. The OBV is mildly bearish, indicating selling pressure. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the bearish indicators from Bollinger Bands and KST.

When is the next results date for JFL Life?

No Upcoming Board Meetings

What is the bonus history of the JFL Life?

JFL Life recently announced a 2:1 bonus issue, where shareholders will receive two additional shares for every one share held as of the record date on September 24, 2024. The ex-date for this bonus is also September 24, 2024.

JFL Life has a recent bonus history where they announced a 2:1 bonus issue. The ex-date for this bonus is set for September 24, 2024. This means that shareholders will receive two additional shares for every one share they hold as of the record date, which is also September 24, 2024.

Has JFL Life declared dividend?

JFL Life Sciences Ltd has declared a 2% dividend, amounting to 0.20 per share, with an ex-date of September 13, 2024. Despite the dividend, the company has experienced significant declines in price returns over various periods, resulting in negative total returns.

JFL Life Sciences Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.20<BR>- Ex-date: 13 Sep 2024<BR><BR>Dividend Yield: 0.34%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -40.45%, the dividend return was 0%, resulting in a total return of -40.45%.<BR><BR>For the 1-year period, the price return was -46.96%, the dividend return was 0.50%, leading to a total return of -46.46%.<BR><BR>Over the 2-year period, the price return was -51.78%, the dividend return was 0.52%, culminating in a total return of -51.26%.<BR><BR>In the 3-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, culminating in a total return of 0.0%.<BR><BR>Overall, while JFL Life has declared a dividend, the total returns over various periods indicate significant declines in price returns, with minimal contributions from dividends. This suggests a challenging performance environment for the company.